ELEV•benzinga•
Elevation Oncology Stops Gastric Cancer Study, Slashes Staff By 70%
Summary
Elevation Oncology ends EO-3021 development after Phase 1 results, shifts focus to EO-1022, and plans a major workforce reduction to extend funding.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on March 20, 2025 by benzinga